New study tracks Real-World impact of teplizumab on diabetes Patients' quality of life
NCT ID NCT07260110
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 22 times
Summary
This study follows 550 people with stage 2 type 1 diabetes in the U.S. to see how their quality of life, anxiety, and diabetes management change over time. It compares those who received the drug teplizumab with those who did not. The goal is to understand the real-world benefits and challenges of treatment, not to test a cure or new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site
RECRUITINGSan Francisco, California, 94107, United States
Conditions
Explore the condition pages connected to this study.